Engitix
Human extracellular matrix (ECM) drug target discovery platform.
Engitix has raised €69M across 2 funding rounds from 3 investors, most recently a Series A round in Jan 2026. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKwww.engitix.com ↗
Total raised
€69M
€69,009,365
Funding rounds
2
Investors
3
distinct backers
Active since
2022-01
latest 2026-01
Funding by year
EUR raised per year · 2026 YTDEngitix — funding by year — interactive chart.
Data table
| Engitix — funding by year | |
|---|---|
| 2022 | €48M |
| 2026 | €21M |
Signals
High confidenceRaise-next likelihood43
base rate 44% for Series A
- ▲ In typical raise window
- ▼ Down/flat last round
Exit likelihood19
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ Recent equity round, but funding momentum is down (may be rescue financing)
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-01-08 | Series A | €21M | Mike Platt,Netherton Investments | View deal → |
| 2022-01-19 | Series A | €48M | Dompé,Netherton Investments | View deal → |
Investors
3Related news
- Engitix Raises $54M in Series A Financingfinsmes.com · 2022-01
- uktech.news
Similar companies
same sector or countryGlobal coverage: FundingData